海南德镁医药科技

Hainan Demei Pharmaceutical Technology is a clinical-stage biotechnology company based in China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on targeting the RAS/MAPK signaling pathway, with a robust pipeline of inhibitors for KRAS G12C, KRAS G12D, SOS1, and SHP2. Demei Pharma utilizes advanced structure-based drug design and medicinal chemistry platforms to address unmet medical needs in oncology, particularly for refractory solid tumors like lung and pancreatic cancers. The company is headquartered in the Hainan Free Trade Port and maintains research and development operations aimed at global commercialization.